KRAS and endometrial carcinoma: An intermediate group with prevalent mutations on both pathways would include endometrial carcinoma (PIK3CA 57%, KRAS 21%), colorectal adenocarcinoma (PIK3CA 31%, KRAS 51%), or gastric adenocarcinoma (PIK3CA 24%, KRAS 16%).